1. Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis
- Author
-
Belingheri, M, Lazzari, L, Parazzi, V, Groppali, E, Biagi, E, Gaipa, G, Giordano, R, Rastaldi, M, Croci, D, Biondi, A, Rebulla, P, Edefonti, A, Ghio, L, BIAGI, ETTORE, GAIPA, GIUSEPPE, BIONDI, ANDREA, Ghio, L., Belingheri, M, Lazzari, L, Parazzi, V, Groppali, E, Biagi, E, Gaipa, G, Giordano, R, Rastaldi, M, Croci, D, Biondi, A, Rebulla, P, Edefonti, A, Ghio, L, BIAGI, ETTORE, GAIPA, GIUSEPPE, BIONDI, ANDREA, and Ghio, L.
- Abstract
Focal segmental glomerulosclerosis (FSGS) is the most frequent acquired renal condition resulting in end stage kidney disease in children. We describe a cell therapy treatment with human allogeneic bone marrow mesenchymal stem cells (MSC) in a 13-year-old patient developing recurrent FSGS after renal transplantation, which was not responding to conventional therapy. This treatment relied on the following measurements:clinical and laboratory evaluation of renal function, proteome array, biopsy, short tandem repeat assay. Before MSC treatment, the patient needed weekly plasmapheresis to achieve proteinuria-to-creatininuria ratio below 5. After three MSC infusions without adverse events, the patient has a stable renal function and the proteinuria target was reached without plasmapheresis. In addition, some circulating inflammatory factors decreased and their levels were still low after one year. This is the first report of an MSC treatment in an FSGS patient. Even though different factors may have contributed to the clinical results, after MSC infusion a stable reduction in the serum level of several inflammatory factors has been registered and the patient does not need anymore plasmapheresis to keep proteinuria under control. In addition, this encouraging single case let us identify some putative efficacy biomarkers that could be of clinical interest in chronic kidney diseases
- Published
- 2013